14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SANA vs LXRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LXRX Captures Overall Composite Edge (38.7 SELL vs 44.3 HOLD), While SANA Leads 3–2 on Growth & Valuation Pillars
LXRX Overall Winner
6-Pillar Tally: SANA 3 – 2 LXRX (1 Tie)
Matrix Metrics: SANA 4 – 4 LXRX
As of Nov 16, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) captures the overall head-to-head institutional edge over Sana Biotechnology, Inc. (SANA) on higher Unified Composite conviction (38.7/100 SELL vs. 44.3/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Balance Sheet & Cash Flow), while SANA wins 3–2 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus LXRX at $1.75 (N/M Forward P/E, -147.4% operating margin).
Composite vs. Pillar Nuance: While SANA currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. LXRX 38.7/100 SELL), LXRX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-147.4% vs. 0.0% operating margin) and revenue trajectory (-20.7% vs. +0.0% YoY).
Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile LXRX is in a Breakdown options structure phase (RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs LXRX. Trailing 12-month operating profitability (SANA 0.0% vs LXRX -147.4%) and valuation multiples (SANA N/M vs LXRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $810.3M market capitalization and -147.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SANA vs LXRX Key Questions & Quantitative Answers
As of Nov 16, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) captures the overall head-to-head institutional edge over Sana Biotechnology, Inc. (SANA) on higher Unified Composite conviction (38.7/100 SELL vs. 44.3/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Balance Sheet & Cash Flow), while SANA wins 3–2 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus LXRX at $1.75 (N/M Forward P/E, -147.4% operating margin). Composite vs. Pillar Nuance: While SANA currently prints a higher short-term Unified Composite Score (44.3/100 HOLD vs. LXRX 38.7/100 SELL), LXRX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-147.4% vs. 0.0% operating margin) and revenue trajectory (-20.7% vs. +0.0% YoY). Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile LXRX is in a Breakdown options structure phase (RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SANA leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LXRX at -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus $39M for LXRX. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LXRX.
LXRX screens cheaper on headline valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 21.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus LXRX (-43.9% ROE) capital efficiency.
In options market volatility and institutional positioning, SANA carries 222.6% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.63β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.